NEW YORK (GenomeWeb News) – Rosetta Genomics said today it has struck an agreement with the University of California, Irvine, School of Medicine to work together to validate diagnostic tests based on the company’s microRNA technology.
 
Under the agreement, the CLIA-certified medical school and the company will work together to validate tests that are designed to differentiate squamous from non-squamous lung cancer and to differentiate mesothelioma from adenocarcinoma, as well as to identify cancers of unknown primary origin.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Congress approved a bill Friday that would increase the US National Institutes of Health's funding by $2 billion for fiscal year 2019.

UK's Labour Party calls for a ban on non-invasive prenatal testing for determining sex, BBC News reports.

Sarah Lawrence College's Laura Hercher warns in a New York Times op-ed that more people are going to need help figuring out what their consumer genetic testing results mean.

In PLOS this week: intra-tumor heterogeneity patterns, genomic analysis of Thoroughbred horse origins, and more.